Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade)
Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...
Pfizer (NYSE:PFE) sheds US$13b, company earnings and investor returns have been trending downwards for past three years
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly.
James Latham (LON:LTHM) shareholders have earned a 11% CAGR over the last five years
It hasn't been the best quarter for James Latham plc ( LON:LTHM ) shareholders, since the share price has fallen 10% ...
HP's (NYSE:HPQ) five-year total shareholder returns outpace the underlying earnings growth
(NYSE:HPQ) shareholders are probably rather concerned to see the share price fall 32% over the last three months. But at least the stock is up over the last five years. However we are not very ...
The three-year earnings decline is not helping Atlantic Union Bankshares' (NYSE:AUB share price, as stock falls another 17% in past week
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the ...